FIG 2. Case 3: 36-year-old man with bifrontal GBM treated with carboplatin and thalidomide, without concomitant steroid therapy.

A–C, Postcontrast T1-weighted images. At the start of therapy, a heterogeneous, irregularly enhancing right frontal GBM with areas of necrosis extends into the contralateral frontal lobe (A). At 3-month follow-up, there is a decrease in contrast enhancement within the bifrontal tumor (B). At 7-month follow-up, there is further decrease in contrast enhancement (C).

D–F, Corresponding color overlay images. At the start of therapy, a focal area of hyperperfusion is seen in the medial aspect of the right frontal tumor (D). At 3-month follow-up, there is an interval decrease in the perfusion abnormality in the right medial frontal lobe tumor (E). At 7-month follow-up, a new focus of hyperperfusion is seen in the left medial frontal lobe (arrow) without corresponding abnormality on conventional T1-weighted image (F).